key: cord-0730588-9johfwul
authors: Boban, Marko
title: Novel coronavirus disease (COVID‐19) update on epidemiology, pathogenicity, clinical course and treatments
date: 2020-12-06
journal: Int J Clin Pract
DOI: 10.1111/ijcp.13868
sha: 7a88199dee6e1206aa1ee601babf95b24c9af6de
doc_id: 730588
cord_uid: 9johfwul

During the December of 2019, a series of patients with pneumonia caused by novel coronavirus; the severe acute respiratory syndrome (SARS) corona (COV‐2), that is, COVID‐19. Since the first cluster of cases was reported in China on 31 December 2019 until the 28 April 2020, there were internationally reported 3’000’000 cases, in over 185 countries, and 207'265 deaths. To date, it is still not unanimously clear which effects parameters of virus and host are important for the development of severe disease course. According to the most updated internationally available online cases register, COVID‐19 disease has mild symptoms in around 85% of cases, there are 3%‐10% of critical cases, and mortality is around 5%‐7%. Since currently there is no available vaccine and no well‐established specific antiviral therapy, numerous agents are being tested in clinical scenarios. The most common regimens include remdesivir, convalescent plasma. Widely used chloroquine, hydroxychloroquine and azithromycin combinations, as well as lopinavir‐ritonavir were shown to have less efficient treatment effects. More severe cases of pneumonia and dyspnoea, or uncontrollable fever are treated as inpatients, and nearly 10% in intensive care units. Oxygen supplementation is indicated to maintain peripheral blood oxygenation over 90%‐96%. Advanced support systems include mechanical ventilation and extracorporeal membranous support; however, those without targeted antiviral therapy represent only temporary bridge for scarce potential restitution in patient themselves. The aim of review is to present current state of the art in epidemiology, pathogenesis, clinical course and treatment of COVID‐19 patients.

there were 2206 (1831 in Saudi Arabia) cases with mortality of 787 (35.7%). 4 Since the first cluster of cases was reported in China on 31

December 2019, COVID-19 virus was isolated on 7 January 2020, there were 41 cases and one death on 11 January 2020. 2 Coronaviridae family is a large group of animal and human viruses made up from single-stranded RNA. COVID-19 is member of sarbecovirus sub-genus, beta-coronavirus, phylogenetically closely related (88%) with two bat-derived SARS-like coronaviruses from Zhoushan, China in 2018; a bit less concordant with SARS-CoV (79%) and MERS-CoV (50%). 7 Similar to other coronaviruses, COVID-19 has four structural proteins spike(S); membrane (M); envelope (E) and nucleocapsid (N). S protein has close resemblance with angiotensin-converting enzyme 2 (ACE-2) receptor on human cells and was confirmed as a receptor for SARS-CoV-2, that is, COVID-19. 8 ACE-2 receptor is abundantly found on respiratory epithelial cells, 9 arterial smooth muscle cells, arterial and venous endothelial cells, as well as in myocardial pericytes, capillary endothelial cells and intramyocardial microvascular network. [10] [11] [12] Due to these particular cell localisations, concordance with COVID-19 predilection organ systems impairments of the endothelial function meaningfully intermediates clinical course. In addition, this is supported with clinical observation of generally worsened course in patients with preexisting comorbidities, particularly cardiovascular, respiratory, metabolic and cancerous diseases. 13 The aim of this review is to present contemporary state of the art around epidemiology, pathogenicity clinical course and treatments of COVID-19 patients worldwide.

Methodological issues around narrative review in regard to novel coronavirus disease are currently exceedingly challenging and those will be cautiously presented in order to point out potential blind spots. Due to the fact that the ongoing pandemic of COVID-19 is of total existence for only a few months, there are numerous limitations in currently available studies and practices. From first characterisation of novel virus in January 2020, until the WHO recognised global epidemic in March 2020, and including the time to the present day, there has been less than 5 months of any data considering the novel disease. Reports on spread of the virus, rate of transmission, incubation periods and prevalence of various clinical entities of COVID-19 disease were changed several times, as the pace of epidemic was outspread in Wuhan, China, to ongoing global pandemics in other countries, particularly Italy, Spain and UK, and to date, the most serious geographical outburst of cases in the United States and Russian federation. Baseline health response was grounded on a set of practices which was as close as possible to earlier known disease entities. For this reason, some initial treatment strategies and salvage therapies were only rather recently shown to be less effective. To the best of authors knowledge, to date, even a single study of prospective randomised controlled settings is not available. The most relevant limitation is concealed in the homogeneity of reporting, study settings and primer outcomes. One must take into notion, that the latter is due to highly variable organisational settings of healthcare systems (including the reporting of the single hospital, sets of hospitals within some local network, through local, regional or national health authorities), local threshold for hospitalisation, variable 

Human to human transmission was confirmed rather early from COVID-19 discovery. 15 Modes of spread are similar to other respiratory viruses and typically include close contacts, via respiratory droplets, produced by sneezing, coughing or even breathing and talking, with initial basic reproductive number of transmissions estimated to be 2.2-3.9. 16, 17 Incubation period was found to be for most of the cases on average between 3 and 5 days, with interval range from 2 days to 2 weeks. 18 Symptomatic patients typically emerge with fever, malaise, nasal congestion, dyspnoea and cough from 4-7 day. 18 Other types of clinical presentation include anosmia, sore throat, fever, muscle weakness, tiredness, headache and diarrhoea. 19 Viral pneumonia develops from day 5 to second or third week, with radiologic signs of ground glass appearance, bilateral patchy con- (32109013). Interestingly, 41.3% of patients received oxygen therapy, 6.1% were on mechanical ventilation and 0.5% had extracorporeal membrane oxygenation (ECMO). 24 Patients with severe disease course were generally older (52 vs. 45 years), one-third of them had one or more chronic comorbidities like hypertension, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease and cancer. 24 were male, 709/1043 (68%) had at least one comorbidity and 509 (49%) had hypertension. 6 Most of the patients needed respiratory support 1287/1300 (99%), of which 137 (11%) had non-invasive support and 1150 (88%) had mechanical respiratory support. During follow-up, which was close to 1 month, only 256 (16%) were discharged, while 920 patients (58%) stayed in the ICU, and 405 (26%) had died (36% mortality rate for patients older than 64). 6 So far, the largest case series of COVID-19 hospitalised patients was in study by Richardson et al from 12 New York hospitals in period between 1

March and 4 April 2020, which included data on 5700 patients, median age was 63 years; 39.7% female. 25 The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%) and diabetes (1808; 33.8%). 25 The number of patients treated in ICU was 373 (14.2%); mechanical invasive ventilation was performed in 320 (12.2%) and total death toll in studied period 553 (9.7%). 25 The effects of mechanical ventilation, due to the narrow timeline of study could hardly be estimated, with 831 (72.2%) persisted in hospital; 38 (3.3%) were discharged alive and 282 (24.5%) died. 25 

Due to the fact that currently there is no available vaccine and no well-established specific antiviral therapy, numerous agents are being tested in clinical scenarios. Milder clinical presentations are treated as quarantined outpatients similar to common flu, with antipyretics, non-steroidal anti-inflammatory drugs, resting and rehydration. In case of more severe course, uncontrollable fever, profound dyspnoea or other high-risk associated factors more optimal treatment actions could be rehearsed only in hospitals. Pronounced dyspnoea and/or hypoxia, mostly due to complications of pneumonia is being treated with oxygen supplementation via nasal catheters/ masks and other modalities discussed in more detail after the common drug regimens.

Remdesivir is a nucleotide analogue prodrug that is metabolised to analogue of adenosine triphosphate and inhibits viral RNA poly- 27 Other studies reported on clinical improvement of cases, as in three of five users in ECMO patients. 28 Eventhough currently there is a general lack in prospective randomised studies, Remdesivir still shows very promising results. One must not disregard the fact that it was only being used in patients with advanced, clinically more severe disease, in which the potential for full recovery might also be limited. Further studies, on larger sample sizes, different COVID-19 stages and patients profile, with additional scenarios would be necessary to finalise its position in treatment of COVID-19, particularly around length of stay, viral titre dynamics, radiological restitution, need for ICU, mortality, potential for outpatient management in daily care. 

If dyspnoea persists and haemoglobin saturation falls below 94%, it is generally recommended to initiate oxygen supplementation, to maintain peripheral saturation levels over 90%-96%. Low flow (up 6o 6L/min) nasal catheters or face-masks are sufficient for dyspnoeic patients. High-flow oxygen via nasal mask is indicated with acute respiratory failure in patients with COVID-19. 45 For the latter, there are active arguments on modality of high-flow oxygen, in terms of non-invasive (using tight fitting face mask) or high-flow via nasal cannula, due to the fact that there is greater potential to outspread viral aerosol of patients. 46, 47 Furthermore, it is also reasonable to think about early intubation and mechanical ventilation in order to bypass the high-flow modes, since it is expected that patients generally will need it and the risk of repeated manipulations and potential of viral outspread in high-flow modes. 48 The most common initial form of ventilation is the low tidal volume in volume-limited assisted mode and positive end expiratory pressure, and further adjustments are being made in order to maintain sufficient oxygenation and decrease potential for barotrauma or oxygen toxicity. 49 One must be cautious in care around patients with ARDS and prolonged intubation due to development of complications in terms of cachexia, secondary infections, hemorheological complications etc Utilisation of nutritional support was even found to be harmful, so further investigations would be warranted. 50 Generally, nebulizers as therapeutic modalities should be avoided in patients with COVID-19.

Extracorporeal membrane oxygenation (ECMO) can be used in form of venovenous or venoarterial modalities, depending on the substitution of oxygenation and/or circulation. Jacobs et al reported on 32 consecutive cases of ECMO in COVID-19 critically ill patients with a 24-day timeline. 28 During the study course, a bit over half 17/32 patients persisted on ECMO, 10 died prior to or shortly after decannulation. 28 Medical therapy in the surviving ECMO patients was as follows: four of five survivors received intravenous steroids, three of five survivors received antiviral medications (Remdesivir), two of five survivors were treated with anti-interleukin-6-receptor monoclonal antibodies and one of five survivors received hydroxychloroquine. 28 Sultan et al reported on use of venovenous ECMO in 10 COVID-19 patients (31-69 years, 70% male), where two patients were discharged and only one patient died from multiorgan failure during the study course. 51 Useful therapeutic possibility of ECMO procedure is availability of cytokine absorption, that is, immunomodulators, which were previously shown to have positive effects in another group of critically ill patients with ARDS and sepsis. 52, 53 One must underscore the fact that oxygen supplementation via mechanical ventilation and/or circulatory support are advanced methodologies of ICU treatment; however, those are still enhancers of acutely diminished body functions. In this way, machines are prolonging life, as a bridge to scarce potential that the patient self-recovers or by adding effective antiviral or other treatments that intervene in dominant pathogen life cycle.

In conclusion, novel coronavirus disease is the most serious pandemic of this millennium. Through several months of human to human air borne transmission, it affected over 3 million population in over 185 states/territories and there are over 220 000 of dead.

Patients with pronounced fever, dyspnoea or pneumonia are generally hospitalised, around 10% of those are critical cases and mortality in currently known cases is estimated to be 4%-7%. The most promising results came from the application of remdesivir and convalescent plasma of survivors; however, further studies are needed in order to define optimal therapeutic management for various types of COVID-19 infection. Supportive measures in intensive care units include mechanical ventilation and extracorporeal membranous oxygenation. Numerous groups are focused on the development of vaccine, which could become available in the months to come.

None declared.

The data that support the findings of this study are openly available in the National library of medicine and its service PubMed at [available at url: https://pubmed.ncbi.nlm.nih.gov/], as reference number and over openly available database, for example, figshare over DOIs and references. Information on epidemiology were obtained from the "Worldmeters" database, on international number of COVID-19 reported cases (available at url: https://www.world omete rs.info/ coron aviru s/#count ries ).

https://orcid.org/0000-0002-6129-575X

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 Admitted to ICUs of the Lombardy region

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Archives of academic emergency medicine

A new system for grading recommendations in evidence based guidelines

Emergence of SARS-like coronavirus poses new challenge in China

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

The relative transmissibility of asymptomatic cases among close contacts

The COVID-19 epidemic

Scientific research progress of COVID-19/ SARS-CoV-2 in the first five months

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus

Viral dynamics in mild and severe cases of COVID-19

Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia

Clinical characteristics of coronavirus disease 2019 in China

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized With COVID-19 in the New York City area

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Compassionate use of remdesivir for patients with severe Covid-19

Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment with convalescent plasma for critically Ill patients with SARS-CoV-2 infection

Treatment with convalescent plasma for COVID-19 patients in Wuhan

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment

Off-label use of tocilizumab in patients with SARS-CoV-2 infection

Tocilizumab treatment in COVID-19: a single center experience

Pleiotropic effects of statins on the cardiovascular system

COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure

Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action

Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents. The Cremona experience

Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection

Exhaled air dispersion during highflow nasal cannula therapy versus CPAP via different masks. The European respiratory journal

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Staff safety during emergency airway management for COVID-19 in Hong Kong

Lung Recruitability in SARS-CoV-2 Associated Acute Respiratory Distress Syndrome: A Single-center

Early exposure to recommended calorie delivery in the intensive care unit is associated with increased mortality in patients with acute respiratory distress syndrome

The role of extracorporeal life support for patients with COVID-19: Preliminary results from a statewide experience

Combined Use of CytoSorb and ECMO in Patients with Severe Pneumogenic Sepsis. The Thoracic and Cardiovascular Surgeon

Blood purification with CytoSorb in critically ill patients: single-center preliminary experience

COVID-19) update on epidemiology, pathogenicity, clinical course and treatments